{"id":"https://openalex.org/W2594000342","doi":"https://doi.org/10.1007/s13300-017-0241-z","title":"Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom","display_name":"Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom","alternate_titles":[],"publication_year":2017,"publication_date":"2017-03-09","ids":{"openalex":"https://openalex.org/W2594000342","doi":"https://doi.org/10.1007/s13300-017-0241-z","mag":"2594000342","pmid":"https://pubmed.ncbi.nlm.nih.gov/28281244","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5380503"},"language":"en","primary_location":{"id":"doi:10.1007/s13300-017-0241-z","doi":"https://doi.org/10.1007/s13300-017-0241-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-017-0241-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-017-0241-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2594000342"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13300-017-0241-z.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084241436","display_name":"Michael D Feher","orcid":"https://orcid.org/0000-0003-0631-6199","observed_orcids":["https://orcid.org/0000-0003-0631-6199"]},"institutions":[{"id":"https://openalex.org/I4210136304","display_name":"Chelsea and Westminster Hospital","ror":"https://ror.org/038zxea36","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799869770","https://openalex.org/I4210136304"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Feher","raw_affiliation_strings":["Chelsea and Westminster Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chelsea and Westminster Hospital, London, UK","institution_ids":["https://openalex.org/I4210136304"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044501689","display_name":"Gabriela Vega-Hernandez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126084","display_name":"Novo Nordisk (United Kingdom)","ror":"https://ror.org/0415cr103","country_code":"GB","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210126084","https://openalex.org/I4210159963"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Gabriela Vega-Hernandez","raw_affiliation_strings":["Novo Nordisk, West Sussex, UK. gvg@novonordisk.com","Novo Nordisk, West Sussex, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, West Sussex, UK. gvg@novonordisk.com","institution_ids":[]},{"raw_affiliation_string":"Novo Nordisk, West Sussex, UK","institution_ids":["https://openalex.org/I4210126084"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084121547","display_name":"Emina Mocevic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Emina Mocevic","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Brian Buysse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brian Buysse","raw_affiliation_strings":["NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077195561","display_name":"Melissa Myland","orcid":"https://orcid.org/0000-0003-2567-3044","observed_orcids":["https://orcid.org/0000-0003-2567-3044"]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Melissa Myland","raw_affiliation_strings":["NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027150219","display_name":"G. Sarah Power","orcid":"https://orcid.org/0009-0008-1847-3902","observed_orcids":["https://orcid.org/0009-0008-1847-3902"]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Geraldine S. Power","raw_affiliation_strings":["NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077914785","display_name":"Lise Lotte N. Husemoen","orcid":"https://orcid.org/0000-0003-2491-642X","observed_orcids":["https://orcid.org/0000-0003-2491-642X"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lise L. Nystrup Husemoen","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joseph Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28927889","display_name":"IQVIA (United Kingdom)","ror":"https://ror.org/040g76k92","country_code":"GB","type":"company","lineage":["https://openalex.org/I28927889","https://openalex.org/I4210108991"]},{"id":"https://openalex.org/I4210089966","display_name":"London School of Hygiene & Tropical Medicine","ror":"https://ror.org/00a0jsq62","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I4210089966"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joseph Kim","raw_affiliation_strings":["Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK","NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK","institution_ids":["https://openalex.org/I4210089966"]},{"raw_affiliation_string":"NEMEA Centre of Excellence for Retrospective Studies, QuintilesIMS, London, UK","institution_ids":["https://openalex.org/I28927889"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036277718","display_name":"Daniel R. Witte","orcid":"https://orcid.org/0000-0002-0769-2922","observed_orcids":["https://orcid.org/0000-0002-0769-2922"]},"institutions":[{"id":"https://openalex.org/I204337017","display_name":"Aarhus University","ror":"https://ror.org/01aj84f44","country_code":"DK","type":"education","lineage":["https://openalex.org/I204337017"]},{"id":"https://openalex.org/I4210157333","display_name":"Danish Diabetes Academy","ror":"https://ror.org/05xbkrn90","country_code":"DK","type":"facility","lineage":["https://openalex.org/I4210157333"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daniel R. Witte","raw_affiliation_strings":["Danish Diabetes Academy, Odense, Denmark","Department of Public Health, Aarhus University, Aarhus, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Danish Diabetes Academy, Odense, Denmark","institution_ids":["https://openalex.org/I4210157333"]},{"raw_affiliation_string":"Department of Public Health, Aarhus University, Aarhus, Denmark","institution_ids":["https://openalex.org/I204337017"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5044501689"],"corresponding_institution_ids":["https://openalex.org/I4210126084"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":2.526,"has_fulltext":true,"cited_by_count":25,"citation_normalized_percentile":{"value":0.89316851,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"8","issue":"2","first_page":"417","last_page":"431"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.996999979019165},{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.949999988079071},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9700000286102295},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9169999957084656},{"id":"https://openalex.org/keywords/hba1c-reduction","display_name":"HbA1c reduction","score":0.8669999837875366},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8169999718666077},{"id":"https://openalex.org/keywords/body-mass-index","display_name":"body mass index","score":0.7699999809265137},{"id":"https://openalex.org/keywords/systolic-blood-pressure","display_name":"systolic blood pressure","score":0.953000009059906},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.9100000262260437},{"id":"https://openalex.org/keywords/primary-care","display_name":"primary care","score":0.6489999890327454},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.7680000066757202},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.8700000047683716}],"concepts":[{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.9848636984825134},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.939415693283081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8639876842498779},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6471983194351196},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5463469624519348},{"id":"https://openalex.org/C2777538456","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated hemoglobin","level":4,"score":0.5457853078842163},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.46939152479171753},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4610888361930847},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4295095205307007},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3203907012939453}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.1007/s13300-017-0241-z","doi":"https://doi.org/10.1007/s13300-017-0241-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-017-0241-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-017-0241-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4243281","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5380503","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5380503","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5380503/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Ther","raw_type":"Text"},{"id":"pmid:28281244","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28281244","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes therapy : research, treatment and education of diabetes and related disorders","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:publications/af0d740e-eb64-446d-8e36-a35a15864a06","doi":null,"is_oa":false,"landing_page_url":"https://www.scopus.com/pages/publications/85016985129","pdf_url":null,"source":{"id":"https://openalex.org/S4306400063","display_name":"Scopus (Elsevier)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Feher, M, Vega-Hernandez, G, Mocevic, E, Buysse, B, Myland, M, Power, G S, Husemoen, L L N, Kim, J & Witte, D R 2017, 'Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes : Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom', Diabetes Therapy, vol. 8, no. 2, pp. 417-431. https://doi.org/10.1007/s13300-017-0241-z","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:researchonline.lshtm.ac.uk:3615797","doi":null,"is_oa":true,"landing_page_url":"https://researchonline.lshtm.ac.uk/id/eprint/3615797/","pdf_url":"https://researchonline.lshtm.ac.uk/id/eprint/3615797/1/Effectiveness%20of%20Liraglutide%20and%20Lixisenatide%20in%20the%20Treatment%20of%20Type%202%20Diabetes.pdf","source":{"id":"https://openalex.org/S4306402527","display_name":"LSHTM Research Online (London School of Hygiene and Tropical Medicine)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210089966","host_organization_name":"London School of Hygiene & Tropical Medicine","host_organization_lineage":["https://openalex.org/I4210089966"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1007/s13300-017-0241-z","doi":"https://doi.org/10.1007/s13300-017-0241-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-017-0241-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-017-0241-z.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2594000342.pdf","grobid_xml":"https://content.openalex.org/works/W2594000342.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W172609984","https://openalex.org/W1783190234","https://openalex.org/W1891975084","https://openalex.org/W1979698089","https://openalex.org/W1983269691","https://openalex.org/W1990162248","https://openalex.org/W1997876373","https://openalex.org/W2045188930","https://openalex.org/W2059909265","https://openalex.org/W2085029787","https://openalex.org/W2093767459","https://openalex.org/W2103274121","https://openalex.org/W2123946565","https://openalex.org/W2144125787","https://openalex.org/W2158666727","https://openalex.org/W2169382415","https://openalex.org/W2213905132","https://openalex.org/W2332599464","https://openalex.org/W2363880557","https://openalex.org/W2400278409","https://openalex.org/W2425644022","https://openalex.org/W2443999297","https://openalex.org/W2473382031","https://openalex.org/W3001949083","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2948135549","https://openalex.org/W1990162248","https://openalex.org/W2473382031","https://openalex.org/W4226061986","https://openalex.org/W2400278409","https://openalex.org/W2545913623","https://openalex.org/W1985556035","https://openalex.org/W2120128459","https://openalex.org/W2778484847","https://openalex.org/W6959097666"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1,63,123,182],"glucagon-like":[2],"peptide-1":[3],"receptor":[4],"agonists":[5],"liraglutide":[6,26,51,83,189,201,222,274,296],"and":[7,81,90,115,137,163,190,257,267],"lixisenatide":[8,53,85,192,207],"are":[9],"effective":[10],"at":[11],"reducing":[12],"glycated":[13],"hemoglobin":[14],"(HbA1c)":[15],"levels":[16],"in":[17,31,54,96,106,109,187],"patients":[18,126],"with":[19,79],"type":[20],"2":[21],"diabetes":[22],"mellitus":[23],"(T2DM).":[24],"Although":[25],"has":[27],"demonstrated":[28],"superior":[29],"efficacy":[30],"head-to-head":[32],"clinical":[33,56],"trials,":[34],"real-world":[35],"evidence":[36],"of":[37,50,125,156,179],"comparative":[38],"effectiveness":[39,49],"is":[40],"lacking.":[41],"This":[42],"observational":[43],"study":[44],"aimed":[45],"to":[46,152,160,220,229,242,302],"assess":[47],"the":[48,97,104,154,273,291],"versus":[52],"UK":[55,68],"practice.":[57],"METHODS:":[58],"Electronic":[59],"medical":[60],"records":[61],"from":[62,290],"Health":[64],"Improvement":[65],"Network":[66],"(THIN)":[67],"primary":[69,183],"care":[70],"database":[71,293],"were":[72,94,144,224,238,270,278],"analyzed.":[73],"Patients":[74],"aged":[75],"\u226518":[76],"years,":[77],"diagnosed":[78],"T2DM,":[80],"prescribed":[82],"or":[84],"between":[86,284],"01":[87],"May":[88],"2013":[89],"31":[91],"December":[92],"2015":[93],"included":[95],"study.":[98],"Adjusted":[99],"linear":[100,197],"regression":[101,198],"models":[102],"compared":[103,176],"difference":[105,210],"mean":[107],"change":[108],"HbA1c,":[110],"body":[111],"mass":[112],"index":[113],"(BMI),":[114],"systolic":[116],"blood":[117],"pressure":[118],"(SBP)":[119],"after":[120],"12-month":[121],"follow-up.":[122],"proportion":[124],"achieving":[127,161],"glycemic":[128,303],"control":[129],"(HbA1c":[130],"<6.5%,":[131],"<7.0%,":[132],"<7.5%);":[133],"HbA1c":[134,162,203,231,244,259],"reduction":[135,139,165,260],">1%;":[136],"weight":[138,164],"\u22653%":[140],"within":[141],"12":[142],"months":[143],"determined.":[145],"Cox":[146],"proportional":[147],"hazards":[148],"modeling":[149],"was":[150,175,185,282],"used":[151],"evaluate":[153],"effect":[155],"treatment":[157,209,285,297],"on":[158],"time":[159],"targets.":[166],"Healthcare":[167],"resource":[168],"use":[169],"(HCRU)":[170],"(GP,":[171],"secondary":[172],"care,":[173],"hospitalizations)":[174],"using":[177],"analysis":[178],"covariance.":[180],"RESULTS:":[181],"outcome":[184],"assessed":[186],"579":[188],"213":[191],"new":[193],"users.":[194],"Fully":[195],"adjusted":[196],"indicated":[199],"that":[200,295],"reduced":[202],"significantly":[204],"more":[205,227,240],"than":[206],"(mean":[208],"-0.30;":[211],"95%":[212],"CI":[213],"-0.56,":[214],"-0.04;":[215],"p":[216,248,254,263],"=":[217,234,264],"0.025).":[218],"Compared":[219],"lixisenatide,":[221],"recipients":[223],"2.5":[225],"times":[226],"likely":[228,241],"achieve":[230,243],"<6.5%":[232],"(p":[233],"0.0002).":[235,265],"Liraglutide":[236],"users":[237],"also":[239],"<7.0%":[245],"(HR":[246,252,261],"2.10;":[247],"<":[249,255],"0.0001),":[250,256],"<7.5%":[251],"1.65;":[253],">1%":[258],"1.29;":[262],"BMI":[266],"SBP":[268],"reductions":[269],"greater":[271],"for":[272],"group":[275],"but":[276],"results":[277,289],"not":[279],"significant.":[280],"HCRU":[281],"comparable":[283],"groups.":[286],"CONCLUSION:":[287],"These":[288],"THIN":[292],"indicate":[294],"provided":[298],"better":[299],"outcomes":[300],"related":[301],"control.":[304],"FUNDING:":[305],"Novo":[306],"Nordisk.":[307]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2594000342","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":8},{"year":2017,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2017-03-16T00:00:00"}
